Nexstim receives NBS 6 therapy system order from US neurology clinic

• Nexstim received an order for its NBS 6 therapy system from a new neurology clinic customer in the US.
• Order covers an NBS 6 Therapy Base Unit cleared by the FDA for major depressive disorder in adults and adolescents.
• System is also cleared as an adjunct treatment for obsessive compulsive disorder.
• Delivered configuration includes a non-disposable setup with reusable head trackers to lower operating costs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexstim Oyj published the original content used to generate this news brief on July 15, 2026, and is solely responsible for the information contained therein.